Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
Dana-Farber Brigham Cancer Center · Memorial Sloan Kettering Cancer Center · +17 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,053
total citations
- FWCI
- 52.19
- Percentile
- 100%
- References
- 33
Citations per year
Authors
20- EAElizabeth A. MittendorfCorresponding
Dana-Farber Brigham Cancer Center
- HZHong Zhang
Memorial Sloan Kettering Cancer Center
- CHCarlos H. Barrios
Pontifícia Universidade Católica do Rio Grande do Sul
- SSShigehira Saji
Fukushima Medical University
- KHKyung Hae Jung
University of Ulsan, Ulsan College, Asan Medical Center
Topics & keywords
Topics
Keywords
- Medicine
- Atezolizumab
- Anthracycline
- Oncology
- Chemotherapy
- Internal medicine
- Placebo
- Nab-paclitaxel
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.